Sage Therapeutics Files 8-K on Executive Changes and Shareholder Votes
| Field | Detail |
|---|---|
| Company | Sage Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, shareholder-vote
TL;DR
Sage Therapeutics filed an 8-K covering exec changes & shareholder votes. Keep an eye on leadership shifts.
AI Summary
Sage Therapeutics, Inc. filed an 8-K on June 11, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. Specific details regarding the individuals involved, the nature of the compensatory arrangements, or the matters voted upon are not elaborated in the provided text.
Why It Matters
This filing indicates potential shifts in leadership or governance at Sage Therapeutics, which could impact the company's strategic direction and operational management.
Risk Assessment
Risk Level: medium — Changes in directors or officers, especially if numerous or at high levels, can signal internal instability or strategic realignments that may affect future performance.
Key Players & Entities
- Sage Therapeutics, Inc. (company) — Registrant
- June 11, 2025 (date) — Date of Earliest Event Reported
- DELAWARE (jurisdiction) — State of incorporation
- 001-36544 (company_id) — Commission File Number
- 55 Cambridge Parkway (address) — Principal executive offices
- Cambridge (city) — Principal executive offices
- MA (state) — Principal executive offices
- 02142 (zip_code) — Principal executive offices
- (617) 299-8380 (phone_number) — Registrant's telephone number
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates reporting on the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific names and details are not provided in the excerpt.
What compensatory arrangements are being reported?
The filing states that compensatory arrangements of certain officers are being reported, but the details of these arrangements are not specified in the provided text.
What matters were submitted to a vote of security holders?
The filing confirms the submission of matters to a vote of security holders, but the nature of these matters is not detailed in the excerpt.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported in this 8-K is June 11, 2025.
What is Sage Therapeutics, Inc.'s Commission File Number?
Sage Therapeutics, Inc.'s Commission File Number is 001-36544.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Sage Therapeutics, Inc..